Coya Therapeutics Announces Publication Of Phase 1 Study On CTLA4-Ig And Interleukin-2 Combination Therapy For ALS In Frontiers In Neurology

Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced Regulatory T cell (Treg) number and suppressive function in patients who were administered a combination of CTLA4-Ig Fusion Protein (CTLA4-Ig) and Low Dose Interleukin-2 (LD IL-2);

Prior to initiating treatment, patients were declining at an average rate of -1.1 points per month on the ALSFRS-R rating scale- At the end of 6 months of treatment, the mean rate of change on the ALSFRS-R was +0.04 points per month.